OS Therapies (OSTX) announced the issuance of U.S. Patent #12,230,738, protecting commercial manufacturing methods for its listeria monocytogenes cancer immunotherapy platform technology into 2040. The company stated the patent covers its lead asset OST-HER2, Phase 3-stage OST-AXIL, Phase 2-stage OST-503, Phase 1-stage OST-504, and eight pre-clinical candidates, as well as OST-HER2’s use in canine osteosarcoma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSTX: